

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
November 21, 2013**

**ORDER GRANTING CONFIDENTIAL TREATMENT
UNDER THE SECURITIES ACT OF 1933**

Myogen, Inc.

File No. 333-108301 - CF#28815

Gilead Sciences, Inc. (successor to Myogen, Inc.) submitted an application under Rule 406 requesting an extension of a previous grant of confidential treatment for information it excluded from the Exhibits to a Form S-1 registration statement filed on August 28, 2003.

Based on representations by Gilead Sciences, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit(s) will not be released to the public for the time period(s) specified:

| | |
|---------------|-------------------------|
| Exhibit 10.17 | through August 31, 2017 |
| Exhibit 10.18 | through August 31, 2017 |
| Exhibit 10.23 | through August 31, 2017 |

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Elizabeth M. Murphy
Secretary